ClinicalTrials.gg
CompletedNCT02024789Updated Oct 25, 2017

A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS)

A Phase 2 interventional study of Placebo and RG1662 in Down Syndrome, sponsored by Hoffmann-La Roche. Completed at 37 sites in 10 countries. Open to participants aged 12 Years to 30 Years. Per ClinicalTrials.gov, last updated 2017-10-25.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
173
Allocation
Randomized
Ages
12 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Down Syndrome by Hoffmann-La Roche — none open to participants now, none under way, none of them phase 3. Down Syndrome · Hoffmann-La Roche.

Started
2014
the only one that year
Phase 2
2 of 10
none open now
Registered
7th of 10
by date

Among the 10 studies in Down Syndrome by Hoffmann-La Roche, this one is the only one that started in 2014, is one of 2 in phase 2, and was the 7th registered.

Down Syndrome

439 studies on the registry are indexed under Down Syndrome; 100 are open to participants now.

Browse Down Syndrome studies →

Open to participants now

None of the 10 studies in Down Syndrome by Hoffmann-La Roche is open now. The open studies under Down Syndrome, anywhere →

Who these studies take

Of the 75 Down Syndrome studies recruiting now, 14 (19%) set no upper age limit and 58 (77%) stop at 75 or younger; 61 take children under 18; 19 take healthy volunteers.

This study: 12 Years to 30 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Down Syndrome by Hoffmann-La Roche as a file.
02

Study summary

This multi-center, randomized, double-blind, 3-arm, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RG1662 in adults and adolescents with Down syndrome. Subjects will be randomized to receive RG1662 either at low or high dose or placebo orally twice daily for 26 weeks.

03

Conditions studied

  • Down Syndrome

Browse trials for

04

Who can participate

Ages eligible
12 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals aged 12-30 years of age inclusive
  • Clinical diagnosis of Down syndrome (trisomy 21) confirmed by chromosomal analysis (karyotyping)
  • Males, or non-pregnant, non-lactating females. For females of , strict prevention is required.
  • Body-mass Index () 18-42 and 15-30 kg/m2 inclusive for adults and adolescents respectively
  • Ability to complete the Clinical Evaluation of Language Fundamentals (CELF)-preschool 2 word classes task
  • Subjects must have a parent, or other reliable caregiver who agrees to accompany the subject to all clinic visits, provide information about the subject as required by the protocol, and ensure compliance with the medication schedule
  • Study participants must have sufficient language, vision and hearing to participate in study evaluations, as judged clinically by investigator

Exclusion criteria

Exclusion Criteria:

  • Subjects with a current DSM 5 diagnosis of any primary psychiatric diagnosis (including ASD or MDD)
  • Subjects with a history of infantile spasms, of West syndrome, Lennox-Gastaut syndrome, Early Infantile Epileptic Encephalopathy or any treatment- epilepsy associated with cognitive or developmental regression, of severe head trauma or CNS infections (e.g. meningitis)
  • Subjects with a known or suspected clinical seizure event of any type within 24 months prior to screening
  • abnormalities at screening or baseline; above 450 ms; personal or family history (first degree relatives) of congenital long QT syndrome
  • Inadequate renal or hepatic function
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
173 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    RG1662 120 mg bid

    Drug: RG1662

  • Experimental
    RG1662 240 mg bid

    Drug: RG1662

Interventions

  • DrugPlacebo

    Orally twice daily, 26 weeks

  • DrugRG1662

    120 mg (80 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks

  • DrugRG1662

    240 mg (160 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks

06

What researchers measure

Primary outcomes

  1. Cognition as assessed by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) sub-tests

    Time frame: 26 weeks

  2. Adaptive behavior as assessed by the Vineland Adaptive Behavior Scales-II (VABS-II) standard scores

    Time frame: 26 weeks

  3. Clinical global impression as assessed by Clinician Rated Global Improvement (CGI-I) scale

    Time frame: 26 weeks

Secondary outcomes

  1. Incidence of abnormal ECG changes

    Time frame: 26 weeks

  2. Abnormal ECG changes in adolescents as compared to baseline

    Time frame: from baseline to Week 26

  3. Safety: Incidence of adverse events

    Time frame: approximately 32 weeks

  4. Incidence of abnormal blood pressure

    Time frame: 26 weeks

  5. RG1662 plasma concentrations

    Time frame: 26 weeks

07

Study locations

37 sites
  • Univ of CA San Diego; Neurosciences Comp.Alzheimer's
    La Jolla, California 92037, United States
  • University of California DAVIS Medical Center; M.I.N.D. Institute, Section of Developmental Behavior
    Sacramento, California 95817, United States
  • Emory University School of Medicine; Department of Human Genetics & Pediatrics
    Decatur, Georgia 30033, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Johns Hopkins Hospital.
    Baltimore, Maryland 21287, United States
  • Massachusette General Hospital; Medical Genetics
    Boston, Massachusetts 02114, United States
  • Duke Clin Rsch Institute
    Durham, North Carolina 27710, United States
  • University of Utah School of Medicine; Department of Pediatrics
    Salt Lake City, Utah 84112, United States
  • University of Wisconsin Madison, Waisman Center
    Madison, Wisconsin 53705, United States
  • FLENI
    Caba, C1428AQK, Argentina
  • Instituto Neurologia Bs As
    Ciudad Autonoma de Bs As, 1426, Argentina
  • True North Clinical Research Kentville
    Kentville, Nova Scotia B4N 4K9, Canada
  • Groupement Hospitalier Est-Hopital Femme Mere enfant/Hospice civils de lyon
    Bron, 69003, France
  • CHU de Montpellier Hopital Arnaud de Villeneuve; de Génétique
    Montpellier, 34295, France
  • Institut Jérôme Lejeune; Neuropsychology
    Paris, 75015, France
  • CHU de Saint Etienne; Service de Génétique
    St Etienne, 42055, France
  • Ospedale Pediatrico Bambino Gesù
    Roma, Lazio 00165, Italy
  • Policlinico Universitario "Agostino Gemelli";Dip. Tutela Salute Donna Bambino Adolescente
    Roma, Lazio 00168, Italy
  • Ospedale Microcitemico; Clinica Pediatrica
    Cagliari, Sardegna 09121, Italy
  • Hospital Dr. Angel Leaño; Pediatria
    Guadalajara, Jalisco 45200, Mexico
  • Clínica Para la Atención del Neurodesarrollo
    Aguascalientes, 20030, Mexico
  • Hospital Universitario Dr. Jose Eleuterio Gonzalez; Pediatria
    Monterrey, 64460, Mexico
  • Hospital Médica Tec 100
    Queretaro, 76000, Mexico
  • Auckland Clinical Studies
    Auckland, 1142, New Zealand
  • University of Otago; Psychological Medicine Department
    Dunedin, 9016, New Zealand
  • Wellington Hospital Research Office
    Wellington, 6021, New Zealand
  • KK Women's and Children's Hospital; Department of Neonatology
    Singapore, 229899, Singapore
  • UVaMID Hospital Santa Caterina;; Servicio de Neurología
    Salt, Girona 17090, Spain
  • Complejo Hospitalario Universitario de Santiago (CHUS); Area Asistencial Integrada de Pediatría
    Santiago de Compostela, La Coruña 15706, Spain
  • IMIM, Human Pharmacology and Clinical Neurosciences,
    Barcelona, 08009, Spain
  • Hospital Universitario de la Princesa; Medicina Interna
    Madrid, 28006, Spain
  • Hospital Infantil Universitario Niño Jesus; Pediatria Social
    Madrid, 28009, Spain
  • Fundación Síndrome de Down; Fundación Síndrome de Down
    Madrid, 28016, Spain
  • Blackpool Teaching Hospitals NHS Foundation Trust; Child Development and Family Support Centre
    Blackpool, United Kingdom
  • Mental Health of Learning Disability, Kent & Medway NHS and Social Care Partnership Trust
    Dartford, Kent, DA2 6PB, United Kingdom
  • Doncaster and Bassetlaw Hospitals NHS Foundation Trust; Doncaster Royal Infirmary
    Doncaster, DN2 5LT, United Kingdom
  • Cornwall Partnership NHS Foundation Trust
    Redruth, TR15 2SP, United Kingdom
08

References and documents

Publications

  • Goeldner C, Kishnani PS, Skotko BG, Casero JL, Hipp JF, Derks M, Hernandez MC, Khwaja O, Lennon-Chrimes S, Noeldeke J, Pellicer S, Squassante L, Visootsak J, Wandel C, Fontoura P, d'Ardhuy XL; Clematis Study Group. A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-alpha5 NAM (basmisanil) on intellectual disability associated with Down syndrome. J Neurodev Disord. 2022 Feb 5;14(1):10. doi: 10.1186/s11689-022-09418-0. PubMed 35123401 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2014 to primary completion in May 2016, 23 months.

Of 21 phase 2 interventional studies under Down Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 61. This study's 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2013
First posted
Dec 31, 2013
StartActual
May 5, 2014
Primary completionActual
May 4, 2016
CompletionActual
May 4, 2016
Last update
Oct 25, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02024789
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 31, 2013
Start date
May 5, 2014
Primary completion
May 4, 2016
Completion
May 4, 2016
Last update
Oct 25, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Basmisanil

Start the discussion